Vivos Inc. (OTCMKTS:RDGL - Get Free Report) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 64,900 shares, a decline of 27.5% from the November 30th total of 89,500 shares. Based on an average daily volume of 2,331,100 shares, the short-interest ratio is currently 0.0 days.
Vivos Trading Down 3.8 %
Shares of OTCMKTS:RDGL traded down $0.00 during mid-day trading on Friday, reaching $0.12. The company had a trading volume of 678,729 shares, compared to its average volume of 1,269,331. Vivos has a one year low of $0.05 and a one year high of $0.26. The company's 50-day moving average price is $0.11 and its 200-day moving average price is $0.14. The firm has a market cap of $50.68 million, a price-to-earnings ratio of -11.54 and a beta of 0.94.
About Vivos
(
Get Free Report)
Vivos Inc, a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals.
Read More
Before you consider Vivos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vivos wasn't on the list.
While Vivos currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
